NEW YORK, Jan 4, 2026, 13:22 ET — Market closed
- Establishment Labs shares closed down 5.5% on Friday at $68.84.
- Investors are focused on the company’s FDA push to expand Motiva implants into breast reconstruction.
- Next catalyst: management’s presentation at the J.P. Morgan Healthcare Conference on Jan. 14.
Establishment Labs Holdings Inc. shares fell 5.5% on Friday, ending at $68.84 and lagging a largely flat Nasdaq on the first trading day of 2026. Yahoo Finance
The move comes as investors sharpen their focus on U.S. growth drivers for the medical device maker, particularly a bid to widen the approved use of its Motiva silicone implants beyond cosmetic breast augmentation and into breast reconstruction.
Establishment Labs said on Dec. 29 it submitted Motiva implants to the U.S. Food and Drug Administration for approval in primary and revision breast reconstruction, a step often described on Wall Street as a “label expansion” because it broadens the uses listed in product labeling. “Expanding our FDA approval from breast augmentation to reconstruction is an important step forward for women’s health,” Jeff Ehrhardt, the company’s North America general manager, said in the release. Establishment Labs
Management is due to address investors again soon. Establishment Labs said Chief Executive Officer Peter Caldini and Chief Financial Officer Raj Denhoy will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14 at 9:45 a.m. PT (12:45 p.m. ET). Establishment Labs
The company, which manufactures in Costa Rica and sells Motiva implants globally, remains loss-making on an annual basis, according to LSEG data on Reuters. Establishment Labs reported 2024 revenue of about $166 million and a net loss of about $85 million, while operating cash flow was negative. Reuters
Technically, Friday’s drop left the stock about 12% below its 52-week high of $78.24, based on the company’s end-of-day quote page, after it swung between $73.70 and $68.66 in the session. Establishment Labs
For investors, the FDA submission matters because breast reconstruction represents a different patient flow from elective procedures and is often tied to oncology care, where surgeons and hospitals can be slower to switch products. Establishment Labs has positioned Motiva’s U.S. rollout as a multi-year share-gain opportunity against larger incumbents in breast implants.
Broader risk sentiment will also be in the mix when markets reopen. Investors are watching next week’s key U.S. economic releases on services and jobs for fresh direction on interest-rate expectations, which can sway higher-growth healthcare names. AP News
But the path is not linear. FDA reviews can stretch, and the agency can ask for additional data; any delay would push out the timing of a reconstruction launch and the revenue ramp investors are modeling. Establishment Labs’ losses and cash burn also leave less room for execution missteps if demand growth slows.
